Foscarnet - Revision history

Aidan: /* Dosing */

2023-10-18T12:55:57Z

Dosing

← Older revision		Revision as of 12:55, 18 October 2023
Line 17:		Line 17:

	==Dosing==		==Dosing==

			=== Adult Dosing ===

			* [[CMV esophagitis]] and [[CMV colitis]]: 60 mg/kg/dose every 8 hours or 90 mg/kg/dose every 12 hours
			* [[CMV retinitis]]: induction with 60 mg/kg/dose every 8 hours or 90 mg/kg/dose every 12 hours, for 14 to 21 days, followed by maintenance with 90 to 120 mg/kg/dose once daily for 3 to 6 months or longer
			* Acyclovir-resistant mucocutaneous [[Herpes simplex virus\|herpes simplex]]: 40 mg/kg/dose every 8 to 12 hours

	===Pediatric Dosing===		===Pediatric Dosing===

Aidan at 14:40, 5 December 2020

2020-12-05T14:40:47Z

← Older revision		Revision as of 14:40, 5 December 2020
Line 22:		Line 22:
	*Induction: foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h		*Induction: foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h
	*Maintenance: foscarnet 90 to 120 mg/kg IV q24h		*Maintenance: foscarnet 90 to 120 mg/kg IV q24h

			=== Administration ===

			* Infusion rate not to exceed 1 mg/kg/min, with adult doses of 60 mg/kg typically infused over 1 hour, and doses of 90 to 120 mg/kg infused over 2 hours

	==Safety==		==Safety==

Aidan at 14:38, 5 December 2020

2020-12-05T14:38:47Z

← Older revision		Revision as of 14:38, 5 December 2020
Line 8:		Line 8:
	*Active against all [[human herpesviruses]]		*Active against all [[human herpesviruses]]

	=== Mechanism of Action ===		===Mechanism of Action===

	* Acts as a pyrophosphate analogue that competitively and reversibly inhibits herpesvirus DNA polymerase, causing premature chain termination of DNA		*Acts as a pyrophosphate analogue that competitively and reversibly inhibits herpesvirus DNA polymerase, causing premature chain termination of DNA

	===Pharmacokinetics and Pharmacodynamics===		===Pharmacokinetics and Pharmacodynamics===
Line 25:		Line 25:
	==Safety==		==Safety==

	=== Adverse Events ===		===Adverse Events===

	*Most common AEs include infusion-related [[nausea]], electrolyte abnormalities, and [[acute kidney injury]]		*Most common AEs include infusion-related [[nausea]], electrolyte abnormalities, and [[acute kidney injury]]
Line 34:		Line 34:
	***Minimize with concurrent IV and oral hydration, antiemetics, and slowing the infusion rate[[CiteRef::jayaweera1997mi]]		***Minimize with concurrent IV and oral hydration, antiemetics, and slowing the infusion rate[[CiteRef::jayaweera1997mi]]
	*Other AEs include:		*Other AEs include:
	**[[Seizure]]		**[[Seizure]], usually in patients with concurrent CNS pathology
	**[[Genital ulcers]]		**[[Genital ulcers]], which slowly heal once the drug is stopped
	**[[Anemia]]		**[[Anemia]]
	**[[Nephrogenic diabetes insipidus]]		**[[Nephrogenic diabetes insipidus]]

	=== Monitoring ===		===Monitoring===

	* Close monitoring of electrolytes and creatinine is required		*Close monitoring of electrolytes and creatinine is required

	[[Category:Antivirals]]		[[Category:Antivirals]]

Aidan at 14:36, 5 December 2020

2020-12-05T14:36:29Z

@@ Line 7: / Line 7: @@
 *Active against all [[human herpesviruses]]
 ===Pharmacokinetics and Pharmacodynamics===
@@ Line 21: / Line 25: @@
 ==Safety==
 [[Category:Antivirals]]

Aidan: /* Safety */

2020-09-14T23:16:26Z

Safety

← Older revision		Revision as of 23:16, 14 September 2020
Line 8:		Line 8:
	*Active against all [[human herpesviruses]]		*Active against all [[human herpesviruses]]

	=== Pharmacokinetics and Pharmacodynamics ===		===Pharmacokinetics and Pharmacodynamics===

	* CSF penetration 66% of serum levels		*CSF penetration 66% of serum levels

	== Dosing ==		==Dosing==

	=== Pediatric Dosing ===		===Pediatric Dosing===

	* Induction: foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h		*Induction: foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h
	* Maintenance: foscarnet 90 to 120 mg/kg IV q24h		*Maintenance: foscarnet 90 to 120 mg/kg IV q24h

	== Safety ==		==Safety==

			*Nephrotoxicity, usually reversible
	* Nephrotoxic
	* ~~Causes electrolyte~~ abnormalities, including [[hypocalcemia]], [[hypophosphatemia]], [[hyperphosphatemia]], [[hypomagnesemia]], and [[hypokalemia]]		*Electrolyte abnormalities, including [[hypocalcemia]], [[hypophosphatemia]], [[hyperphosphatemia]], [[hypomagnesemia]], and [[hypokalemia]]
			*Seizures
			*Genital ulcers
			*Anemia
			*Nausea

	[[Category:Antivirals]]		[[Category:Antivirals]]

Aidan at 01:20, 12 September 2020

2020-09-12T01:20:12Z

← Older revision		Revision as of 01:20, 12 September 2020
Line 1:		Line 1:
	== Background ==		==Background==

	*Inhibits DNA polymerase in [[human herpesviruses]]		*Inhibits DNA polymerase in [[human herpesviruses]]
	*Indications: {{#ask: [[Is treated by::foscarnet]] \| default=none}}		*Indications: {{#ask: [[Is treated by::foscarnet]] \| default=none}}

	=== Spectrum of Activity ===		===Spectrum of Activity===

	* Active against all [[human herpesviruses]]		*Active against all [[human herpesviruses]]

			=== Pharmacokinetics and Pharmacodynamics ===

			* CSF penetration 66% of serum levels

			== Dosing ==

			=== Pediatric Dosing ===

			* Induction: foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h
			* Maintenance: foscarnet 90 to 120 mg/kg IV q24h

			== Safety ==

			* Nephrotoxic
			* Causes electrolyte abnormalities, including [[hypocalcemia]], [[hypophosphatemia]], [[hyperphosphatemia]], [[hypomagnesemia]], and [[hypokalemia]]

	[[Category:Antivirals]]		[[Category:Antivirals]]

Aidan at 01:14, 12 September 2020

2020-09-12T01:14:46Z

← Older revision		Revision as of 01:14, 12 September 2020
Line 1:		Line 1:
			== Background ==
⚫	* Inhibits DNA polymerase in [[human herpesviruses]]

⚫	* Indications: {{#ask: [[Is treated by::foscarnet]] \| default=none}}
		⚫	*Inhibits DNA polymerase in [[human herpesviruses]]
		⚫	*Indications: {{#ask: [[Is treated by::foscarnet]] \| default=none}}

			=== Spectrum of Activity ===

			* Active against all [[human herpesviruses]]

	[[Category:Antivirals]]		[[Category:Antivirals]]

Aidan: Created page with "* Inhibits DNA polymerase in human herpesviruses * Indications: {{#ask: Is treated by::foscarnet | default=none}} Category:Antivirals"

2019-10-24T02:00:15Z

Created page with "* Inhibits DNA polymerase in human herpesviruses * Indications: {{#ask: Is treated by::foscarnet | default=none}} Category:Antivirals"

New page

* Inhibits DNA polymerase in [[human herpesviruses]]
* Indications: {{#ask: [[Is treated by::foscarnet]] | default=none}}

[[Category:Antivirals]]